Protective Effects of the Ethyl Acetate Fraction of Distylium racemosum Against Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as non-alcoholic steatohepatitis (NASH), which is a progressive non-alcoholic fatty liver disease, is accompanied by hepatic steatosis, inflammation, and fibrosis. Despite its increasing prevalence, available treatment options for MASH are limited. Here, we investigated the protective effects of the Distylium racemosum ethyl acetate fraction (DRE) using MASH models and explored its key physiologically active components. Palmitic acid (PA)-induced AML12 hepatocytes and high-fat methionine- and choline-deficient-fed C57BL/6 mice were used as MASH models. Lipid accumulation was evaluated via triglyceride measurement, oil red O staining, and histological analysis. Lipid accumulation, inflammation, and fibrosis-associated gene expression were evaluated via real-time polymerase chain reaction. The physiologically active components of DRE were identified via high-performance liquid chromatography. Lipid accumulation and triglyceride levels were significantly reduced in PA-treated AML12 cells following DRE treatment. Additionally, DRE inhibited the expression of genes involved in lipogenesis (FAS and SREBP1c), inflammation (CD68, IL-6, and MCP-1), and fibrosis (COL1A1, COL1A2, and TIMP1). DRE reduced the liver weight, liver-to-body weight ratio, and hepatic steatosis in MASH model mice. It increased carnitine palmitoyltransferase-1 levels and decreased CD36 and transforming growth factor-β levels in the MASH mouse liver. High-performance liquid chromatography revealed that the extract contained rutin flavonoid family members. Overall, DRE was involved in lipid metabolism, inflammation, and fibrosis regulation, exerting potent hepatoprotective effects partly attributed to rutin and serving as a potential preventive candidate for MASH.

• Publication year

  2025

• Venue

  Applied Sciences

• Publication date

  2025-06-27

• Fields of study

  Not labeled

• Identifiers
  DOI 10.3390/app15137238
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• NAFLD and NASH: etiology, targets and emerging therapies.

  2024cited by this paper
• The Effectiveness of Curcumin, Resveratrol, and Silymarin on MASLD: A Systematic Review and Meta‐Analysis

  2024cited by this paper
• Onion Peel Quercetin Attenuates Ethanol-Induced Liver Injury in Mice by Preventing Oxidative Stress and Steatosis

  2022cited by this paper
• Current treatment paradigms and emerging therapies for NAFLD/NASH.

  2021cited by this paper
• Immune cell-mediated features of non-alcoholic steatohepatitis

  2021cited by this paper
• Non-alcoholic fatty liver disease

  2021cited by this paper
• Nonalcoholic fatty liver disease: another leap forward

  2021cited by this paper
• Nonalcoholic Steatohepatitis: A Review.

  2020cited by this paper
• Inhibition of lipid accumulation by the ethyl acetate fraction of Distylium racemosum in vitro and in vivo

  2019cited by this paper
• Gomisin N Alleviates Ethanol-Induced Liver Injury through Ameliorating Lipid Metabolism and Oxidative Stress

  2018cited by this paper
• Hepatoprotective Effects of Sophoricoside against Fructose-Induced Liver Injury via Regulating Lipid Metabolism, Oxidation, and Inflammation in Mice.

  2018cited by this paper
• Mechanisms of NAFLD development and therapeutic strategies

  2018cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• The Pharmacological Potential of Rutin

  2016cited by this paper
• Mulberry leaves (Morus alba L.) ameliorate obesity-induced hepatic lipogenesis, fibrosis, and oxidative stress in high-fat diet-fed mice

  2015cited by this paper
• Herbal Medicines for the Treatment of Nonalcoholic Steatohepatitis: Current Scenario and Future Prospects

  2014cited by this paper
• Novel insights of dietary polyphenols and obesity.

  2014cited by this paper
• Silybin and the liver: from basic research to clinical practice.

  2011cited by this paper
• Nonalcoholic fatty liver disease: pathology and pathogenesis.

  2010cited by this paper
• Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies

  2007cited by this paper

• No citing papers are available for this paper.